Acute Resistance Exercise and Hydrolyzed Collagen Supplementation
Launched by ROB ERSKINE · Jan 24, 2024
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
This study aimed to investigate the effect of different doses of hydrolyzed collagen (HC) with resistance exercise (RE) on whole body collagen synthesis in healthy middle-aged males and females.
Healthy middle-aged males and females ingested 0 grams, 15 grams or 30 grams HC with 50 milligrams vitamin C 1h prior to performing four sets' leg press RE at 10-repetition maximum load, after which they rested for six hours. Blood samples were collected throughout each trial to analyse procollagen type Ⅰ N-terminal propeptide (PⅠNP, a biomarker of collagen synthesis) and β-isomerized C-terminal te...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 12 months experienced in resistance exercise (including weekly lower body exercise)
- • Free from musculoskeletal injury
- Exclusion Criteria:
- • Having a history of patellar tendon pathology
- • Vegan
- • Consumed nutritional supplements or medication purported to have beneficial effects on muscle-tendon properties (e.g. antioxidants, protein, etc.)
- • Had a sustained a lower limb injury in the previous six months
- • Smoker/vaper
- • Having reached menopause (only for middle-aged female participants)
About Rob Erskine
Rob Erskine is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous study design and execution. With a focus on delivering high-quality clinical trials across various therapeutic areas, Rob Erskine emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure the integrity and reliability of data. The organization is driven by a mission to improve patient outcomes by facilitating the development of safe and effective treatments, while upholding the highest ethical standards and compliance with regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liverpool, , United Kingdom
Patients applied
Trial Officials
Robert M Erskine
Principal Investigator
Liverpool John Moores University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported